12:08 PM EDT, 06/18/2025 (MT Newswires) -- Maia Biotechnology ( MAIA ) shares were up Wednesday after the company said it has signed a clinical master supply agreement with Roche.

The deal will support future studies testing Maia's cancer drug candidate, ateganosine, alongside Roche's checkpoint inhibitor, atezolizumab, the company said.

The combination will be studied as a potential treatment for several difficult-to-treat cancers, Maia Biotechnology ( MAIA ) said.

Price: 1.87, Change: +0.21, Percent Change: +12.71